Biperiden-Induced Delirium In A Five-Years Old Child

Author(s): Duygu Kınay, Ahmet Zihni Soyata*.

Journal Name: Current Drug Safety

Volume 14 , Issue 1 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Objective: Extrapyramidal adverse effects of antipsychotic drugs are more reported in children. Biperiden is an anticholinergic agent to treat the adverse effects of antipsychotic drugs. The drug has the potential to induce delirium at toxic doses. However, data are scarce about delirium associated with biperiden in children. Thus far, a case of delirium has been associated with biperiden in an adolescent patient. We report the first case of delirium associated with the use of biperiden in a preadolescent patient.

Case Report: A boy aged five years and weighing 20 kilograms had been diagnosed as having oppositional defiant disorder and separation anxiety disorder in the previous treatment center. Ten milligrams fluoxetine and 0.25 milligrams risperidone had been initiated. On the third day of treatment, dystonia developed and he was administered with biperiden. An hour later, he was brought to our emergency clinic due to disorganized speech and behavior. His vital signs were stable. There were no findings in blood and urine tests. No electrolyte imbalance, liver, kidney, and thyroid dysfunction have been observed. His neurologic examination was unremarkable and no abnormal findings were shown on cranial magnetic resonance imaging. No other system findings or findings pointing out to infectious diseases have been observed. One milligram physostigmine was administered with intravenous infusion. However, symptoms did not resolve and he was diagnosed with delirium. Naranjo Adverse Drug Reaction Probability Scale score was seven, indicating a “Probable” Adverse Drug Reaction. Half milligram haloperidol was administered bid for three days and he was discharged with complete recovery.

Conclusion: Clinicians must be aware of the risk of delirium when using non-toxic doses of biperiden in young children.

Keywords: Adverse effects, anticholinergic drugs, antipsychotics, delirium, psychiatry, psychopharmacology.

[1]
Neufeld KJ, Thomas C. Delirium: Definition, epidemiology, and diagnosis. J Clin Neurophysiol 2013; 30: 438-42.
[2]
Hatherill S, Flischer AJ. Delirium in children and adolescents: A systematic review of the literature. J Psychosom Res 2010; 68: 337-44.
[3]
Cohen D, Bonnot O, Bodeau N, Consoli A, Laurent C. Adverse effects of second-generation antipsychotics in children and adolescents: A Bayesian meta-analysis. J Clin Psychopharmacol 2012; 32: 309-16.
[4]
Wang LJ, Sun CL, Huang YL. Biperiden-induced delirium in an adolescent patient. J Child Adolesc Psychopharmacol 2011; 21: 499-500.
[5]
Traube C, Silver G, Kearney J, et al. Cornell assessment of pediatric delirium: A valid, rapid, observational tool for screening delirium in the PICU. Crit Care Med 2014; 42: 656-63.
[6]
Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45.
[7]
Birmaher B, Axelson DA, Monk K, et al. Fluoxetine for the treatment of childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 2003; 42: 415-23.
[8]
Biederman J, Mick E, Dougherty M, Aleardi M, Wozniak J. An open-label trial of risperidone in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 2005; 15: 311-7.
[9]
Perry E, Walker M, Grace J, Perry R. Acetylcholine in mind: A neurotransmitter correlate of consciousness? Trends Neurosci 1999; 22: 273-80.
[10]
Campbell N, Boustani M, Limbil T, Ott C, Fox C, Maidment I. The cognitive impact of anticholinergics: A clinical review. Clin Interv Aging 2009; 4: 225-33.
[11]
Grimaldi R, Perucca E, Rubero G, et al. Pharmacokinetic and pharmacodynamic studies following the intravenous and oral administration of the antiparkinsonian drug biperiden to normal subjects. Eur J Clin Pharmacol 1986; 29: 735-7.
[12]
Hewer W, Biedert S. Delirium syndrome in biperiden poisoning in German. Fortschr Neurol Psychiatr 1988; 56: 133-6.
[13]
Kojima T, Matsushima E, Ando K. Eyes and the mind. Japan Scientific Societies Press, Tokyo 2000.
[14]
Tamura Y, Chiba S, Takasaki H, Tabata K, Ishimaru Y, Ishimoto T. Biperiden-induced delirium model in rats: A behavioral and electroencephalographic study. Brain Res 2006; 1115: 194-9.
[15]
Shinohara Y. Delirium caused by intramuscular administration of biperiden. J Neuropsychiatry Clin Neurosci 2010; 22: E15.
[16]
Gareri P, De Fazio P, Cotroneo A, et al. Anticholinergic drug-induced delirium in an elderly Alzheimer’s dementia patient. Arch Gerontol Geriatr 2007; 44(Suppl. 1): 199-206.
[17]
Frascogna N. Physostigmine: Is there a role for this antidote in pediatric poisonings? Curr Opin Pediatr 2007; 19: 201-5.
[18]
Hail SL, Obafemi A, Kleinschmidt KC. Successful management of olanzapine-induced anticholinergic agitation and delirium with a continuous intravenous infusion of physostigmine in a pediatric patient. Clin Toxicol (Phila) 2013; 51: 162-6.
[19]
Grover S, Malhotra S, Bharadwaj R, Bn S, Kumar S. Delirium in children and adolescents. Int J Psychiatry Med 2009; 39: 179-87.
[20]
Prugh DG, Wagonfield S, Metcalf D, Jordan K. A clinical study of delirium in children and adolescents. Psychosom Med 1980; 42(1)(Suppl.): 177-95.
[21]
Kain ZN, Caldwell-Andrews AA, Maranets I, et al. Preoperative anxiety and emergence delirium and post-operative maladaptive behaviours. Anesth Analg 2004; 99: 1648-54.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 14
ISSUE: 1
Year: 2019
Page: [48 - 50]
Pages: 3
DOI: 10.2174/1574886313666181029101830
Price: $65

Article Metrics

PDF: 42
HTML: 2
EPUB: 1
PRC: 1